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patients undergoing hemodialysis (HD) or peritoneal dialysis (PD)
in São Paulo, Brazil. Methods: Inclusion criteria for this is a 1-year
rospective study included being 18 years of age or older and clinically
table receiving chronic dialysis. Quality of life was measured using the
F-12 and the Kidney Disease Quality of Life questionnaires at baseline,
months, and 12 months. Patients who completed the surveys for all
hree periods were evaluated. Differences in quality of life scores were
easured using univariate and multivariate regression analyses.
esults: One hundred eighty-nine of 249 (76%) HD patients and 161 of
28 (71%) PD patients completed all three surveys. The PD group was
lder and a larger number had diabetes. PD patients consistently had
igher scores than HD patients at all three measurement periods for
atient satisfaction (P  0.002, P  0.005, and P  0.005, respectively),encouragement/support from staff (P  0.003, P  0.017, and P  0.029,
stud
spon
Univ
al So
oi:10.1016/j.jval.2011.05.016respectively), and burden of kidney disease (P  0.003, P  0.017, and
P 0.057, respectively). The HD group had a greater percent of patients
who clinically improved from baseline to 12 months compared to PD
patients for sleep quality, social support, encouragement/support from
staff, and overall health. Scores for other dimensions of the Kidney
Disease Quality of Life and SF-12 questionnaires were not significantly
different between the PD and HD groups. Conclusions: The results
provide evidence that PD and HD patients have equivalent health-re-
lated quality of life in several domains, although the former performed
better in some quality of life domains despite being older and having
more comorbidities.
Keywords: chronic disease, hemodialysis, peritoneal dialysis, quality of
life.
Copyright © 2011, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Health status and health-related quality of life (HRQoL) are core com-
ponents of health outcomes. HRQoL measures can be assessed with
both generic and disease-specific instruments [1]. Renal replacement
therapy (RRT) is a life-saving treatment for patients with end-stage
renal disease. The two main treatment modalities are transplanta-
tion and dialysis (i.e., hemodialysis [HD] or peritoneal dialysis [PD])
[2,3]. Because of an increase in survival rates for patients with end-
stage renal disease, HRQoL has become increasingly important as an
outcome measure in the evaluation of dialysis treatments. [4] It has
lso been suggested that for patients receiving RRT, quality of life
easures can be used to predict future morbidity and mortality [5].
Studies examining the difference in quality of life outcomes associ-
ated with HD and PD have mixed results [4,5].
More than 77,000 patients in Brazil were receiving chronic di-
lysis during January 2009 [6]; ranking the country among the top
hree in the world in terms of absolute number of dialysis patients.
owever, in Brazil, as in most developing countries, there have
een no known prospective studies completed comparing HRQoL
n HD and PD populations. This study is part of a larger one eval-
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ublished by Elsevier Inc.uating economic aspects of dialysis therapy, and aims to investi-
gate the impact of PD and HD on HRQoL.
Patients and Methods
Study Population
This study recruited PD and HD patients older than age 18 years
who had been on the same dialysis modality for at least 1 month.
Patients were identified from six dialysis centers in São Paulo,
Brazil. Exclusion criteria included hospitalized patients at time of
study initiation and patients who planned to transfer from their
modality within six months.
A similar number of PD and HD patients were selected. HD pa-
tients were randomly selected and matched to PD counterparts who
started dialysis during the 9-month enrollment period, by sex, age
group (45 years, 45–59 years, and60 years), and dialysis center. At
the beginning of the enrollment period, we assessed all patients re-
ceiving dialysis and selected new patients meeting the inclusion cri-
teria who started dialysis during the 9-month enrollment period. All
PD patients at each center meeting the inclusion criteria were se-
y.
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prespecified strata of sex and age, the HD patients were subsequently
selected. This allowed us to reach the desired sample size of approx-
imately 150 patients per group, which provided 80% power to detect
a 10% or greater between-group difference in the mean scores of the
quality of life dimensions.
This was a prospective multicenter study with 1 year of follow-
up. For the purpose of this article, only patients who completed 12
months of follow-up were included in the analysis.
Assessment of HRQoL
The SF-12 (mental component summary and physical component
summary scores) and the Kidney Disease Quality of Life Short
Form (KDQoL-SF) questionnaires were used to assess HRQoL.
Originally, the KDQOL-SF is a self-reported measure that as-
sesses the functioning and well-being of people with kidney dis-
ease and receiving dialysis [7]. The questionnaire consists of 80
items divided into 19 dimensions: SF-36 (eight dimensions/36
items): physical functioning (10 items), role limitations caused by
physical problems (four items), role limitations caused by emo-
tional problems (three items), pain (two items), general health per-
ceptions (five items), social functioning (two items), emotional
well-being (five items), energy/fatigue (four items), and one item
about health status compared to 1 year ago; kidney-disease-tar-
geted items (11 dimensions/43 items): symptom/problem list (12
items), effects of kidney disease (eight items), burden of kidney
disease (four items), cognitive function (three items), quality of
social interaction (three items), sexual function (two items), sleep
(four items), social support (two items), work status (two items),
overall health rating (one item scored separately), patient satisfac-
tion (one item), and dialysis staff encouragement (two items). In
this study, we used the SF-12, instead of SF-36. The SF-12 health
survey is designed to be quick to use while retaining the validity of
the parent SF-36 and the capacity to distinguish between the
health of groups of subjects of different age and sex, and with
different conditions. The loss of reliability associated with fewer
defined health levels was regarded as an acceptable trade-off with
practicality and length in the context of large group studies [8]. The
scales range from 0 to 100, with a higher score representing better
HRQoL [8,9]. From the specific KDQoL domains, we also derived a
kidney disease component summary score [8,9].
Other Data Sources
Medical,clinical,andlaboratorydatawerecollectedatbaselinebydirect
interview with the patient and their charts. All clinical and HRQoL data
were collected at baseline, and at 6 and 12 months of follow-up.
Statistical Analysis
To compare differences in the means between HD and PD for the
three time periods, t tests were used. Benjamini and Hochberg pro-
cedures were applied to evaluate changes in quality of life [10]. Clin-
ically significant changes in quality of life for the individual domains
were defined as a difference of  5 points [10]. Clinically significant
changes for the physical component scores and mental component
scores are defined as 5.7 points and 6.3 points, respectively [10].
Potential independent variables included age category, sex, race, co-
morbities, lab values, comorbities (0 and 1 were dummy variables),
dialysis modality (0  PD, 1  HD) and years receiving dialysis. A P
value less than 0.05 was considered statistically significant and was
retained in the final regression model. We used one multivariate
regression to compare the influence of dialysis modalities on the
quality of life domains for all three time periods and another to ex-
amine the impact of PD and HD on the change in quality of life scores
from baseline to 12 months [10,11]. Adjusters used in the analysis
included demographics, comorbidities, lab values (albumin and he-
moglobin), time receiving dialysis (in years), and type of health insur-ance (public or private). The baseline score was included as an adjus-
tor in the regression analyses evaluating the change in score from
baseline to 12 months.
Statistical analyses were conducted using SAS software, ver-
sion 9.1.3, 2009 (SAS Institute Inc., Cary, NC).
The study was approved by the Committee for Ethics in Re-
search at the Federal University of São Paulo.
Results
Between April 2007 and February 2009, 249 HD patients and 228 PD
patients were interviewed. 189 (76%) HD patients and 161 (71%) PD
patients completed the 12-month study. Of the whole sample, 60
HD patients did not participate in the study due to the following
reasons: 14 died, three received a transplant, six changed dialysis
modality, 28 had less than 12 months of follow-up, four moved to
a different dialysis center, and five were lost to follow-up. Among
PD patients nonparticipation reasons were 12 died, three received
a transplant, 17 changed dialysis modality, 26 had less than 12
months of follow-up, three moved to a different dialysis center,
and six were lost to follow-up. Demographic and socioeconomic
profiles of patients completing all three quality of life surveys are
shown in Table 1 in Supplemental Materials found at: doi:10.1016/
j.jval.2011.05.016. PD patients were older (P  0.009), had fewer
years on dialysis (P  0.003) and have higher rates of diabetes (P 
0.04). Quality of life scores for PD patients at baseline were signif-
icantly higher than for HD patients for several domains, including
effects and burden of kidney disease, work status, encouragement
from dialysis staff, patient satisfaction with care, and kidney dis-
ease component score. Analysis after 6 months showed that bur-
den of kidney disease, encouragement/support from staff, and pa-
tient satisfaction with care scores remained significantly in favor
of PD and, at the end of 12 months, encouragement/support from
staff and patient satisfaction with care domains continued to be
significantly higher in PD compared to HD patients (Table 2 in
Supplemental Materials found at: doi:10.1016/j.jval.2011.05.016). A
greater percent of patients receiving HD compared to PD had clin-
ically significant improvements in HRQoL from baseline to 12
months (P  0.004). Regression analyses showed that at baseline,
burden of kidney disease, effects of kidney disease, dialysis staff
encouragement, overall health rating, patient satisfaction with
care, work status, and kidney disease component summary score
were significantly better for the PD group. At 6 and 12 months,
burden of kidney disease, staff encouragement/support, and pa-
tient satisfaction continued to be better in PD patients (Table 3 in
Supplemental Materials found at: doi:10.1016/j.jval.2011.05.016).
Finally, a further multivariate regression analysis regarding the
change in quality of life from baseline to 12 months showed that HD
significantly improved by 4.86 points (P 0.0285) compared to PD on
quality of social interaction. For patient satisfaction, PD patients im-
proved by 4.85 points (P  0.0275) compared to HD patients from
aseline to 12 months. There was no other significant influence of
ialysis modality on the other HRQoL domains.
Discussion
Dialysis care has increased in importance throughout the world
because of the growing prevalence of patients receiving RRT and
its related morbidity and mortality and high social and financial
costs [12]. There is limited prospective evidence analyzing the bur-
den of both dialysis modalities on HRQoL. This study aimed at
describing HRQoL within the context of dialysis care. At baseline,
both study groups were similar in sex, race, and several comor-
bidities, but PD patients were older, had higher rates of diabetes
and hypertension, and were on dialysis for a shorter time period
than HD patients. Although this could be considered a limitation
of our study, these differences correspond to the reality of the
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of the patients in this study intended to preserve their main char-
acteristics observed in the general dialysis population in Brazil,
namely the greater age and comorbidity in the PD group [12].
Therefore, patients’ matching between the groups at the enroll-
ment was not too strict. In addition, an extensive multivariate
linear regression analysis was performed, adjusting for a number
of baseline characteristics. Patients receiving PD had better scores
in several quality of life domains throughout the study period,
even after adjusting for several factors, including age and comor-
bidity. However, considering that dialysis treatment is chronic,
maybe these statistically significant results could need more time
of observation to have better comprehension regarding the clini-
cally significance results.
Previous research has found little difference in the HRQoL be-
tween patients using HD and PD [5,12]. Liem et al. [5] conducted a
systematic review on HRQoL of HD and PD, as well as transplant
patients. They did not find statistically or clinically significant dif-
ferences between dialysis modalities. So far, we know of no pro-
spective study that looked at HRQoL in both dialysis modalities in
a developing country. Because only 10% of all chronic dialysis pa-
tients in Brazil are receiving PD, we increased the representative-
ness of this group to better evaluate it [12]. HD is the most com-
monly used dialysis modality in many developing countries [12].
In Brazil, the reasons for the predominant allocation of patients on
HD involve clinical, political, social, and economic factors [12].
Our findings show that several QOL dimensions were systemati-
cally better for PD patients during the follow-up, particularly burden
of kidney disease, encouragement from staff, and satisfaction with
care. Considering the clinically significant changes over time, HD had
greater improvement in sleep, social support, and health status and
did worse in cognitive status compared to PD. However, these results
should be interpreted with caution because HD patients started with
an overall lower quality of life evaluation. Literature on the respon-
siveness of different quality of life measures is growing, but this ev-
idence is not available for all quality of life instruments [13]. To min-
imize potential floor and ceiling effects, the literature recommends
the inclusion of the baseline quality of life measure as a covariate in
the selected statistical model (as we did in this study), in which the
contribution of the baseline to the follow-up scores is directly esti-
mated. In general, this will result in a more powerful test of the treat-
ment effect and an unbiased estimate of change [13]. In addition, we
applied the Benjamin and Hochberg method, which is suitable for mul-
tiple comparisons [10]. From the methodologic perspective, we used the
absolute change to analyze significant clinical changes between the
groups over time [10]. Another limitation is that this is an observational
study and some other confounding factors may not have been com-
pletely adjusted in the comparative analysis between PD and HD. Fi-
nally, the cases analyzed with complete follow-up corresponded to
about 75% of the whole sample; nonetheless the patients not included
in this report did not have significant differences in clinical and demo-
graphic parameters compared with those analyzed.
A strength of this study is the prospective design, which has
been rarely used in previous studies on this issue. As such, it
shows how quality of life is subject to variation over time due to
ageing, development of complications, changes in comorbidity, or
due to a patient’s adjustment to the treatment.
The HRQoL tools were applied at baseline, 6 months, and 12
months. For the purpose of this article, we analyzed patients who
participated during the full study period. This study is a first step
in the development of more comprehensive evidence of the
HRQoL benefits of PD compared to HD in developing countries.
Finally, this study was carried out in São Paulo, which is the
main region for RRT in the country. Census data indicate that the
distribution of demographic characteristics of São Paulo, com-pared with other major metropolitan areas in Brazil, are similar
[14]. Despite the mentioned limitations, this study contributes to
the emergent investigation of quality of life and its consequences
to decisions in clinical practice and heath policy in RRT. This pro-
spective study provides evidence that quality of life is, in general,
similar for PD and HD patients with some domains favoring PD.
These findings could be used in the planning of health care ser-
vices and patient management.
Conclusions
There was no difference between PD and HD patients’ scores on the
SF-12 instrument. PD consistently performed better than HD on bur-
den of kidney disease, patient satisfaction, and staff encouragement/
support domains. HD had greater clinical improvements on several
variables but they had started lower at baseline and thus had more
room for improvement. However, these differences are not clinically
significant. Future analyses should compare incident HD and PD pa-
tients and use more sophisticated matching techniques.
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